HCL-GROUP
18.1.2023 12:37:33 CET | Business Wire | Press release
Securing the world’s global freshwater ecosystems, under increasing threat from climate change, population growth and consumer demand, has become more critical than ever. To tackle this escalating crisis, UpLink, the open innovation platform of the World Economic Forum, in partnership with global conglomerate HCL Group, has announced 10 water-focused entrepreneurs who will share CHF1.75 million ($1.9 million) from HCL Group to scale their innovations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118005448/en/
Access to water plays a critical role in food production, education, job creation, health and well-being and the preservation of the natural world and is vital to achieving the UN’s 2030 sustainability agenda. However, global demand for water will exceed sustainable supply by 40% by 2030, with huge implications for the global economy and society.
The 10 start-ups are the winners of the Global Freshwater Innovation Challenge, the first of five challenges under HCL and UpLink’s Aquapreneur Innovation Initiative. Launched in September 2022, the challenge called for innovative solutions that would strengthen data-driven decision making, improve freshwater resilience in the face of climate change and restore water quality around the world.
Through a $15 million investment over five years, HCL Group is supporting UpLink and the Forum’s Global Water Initiative to launch a series of innovation challenges and create an innovation ecosystem for the global freshwater sector on UpLink.
The 10 water-focused entrepreneurs, or “aquapreneurs”, were chosen from 227 solutions submitted to the challenge, and will now each receive CHF175,000 ($190,000) in vital funding from HCL Group. Two of these innovators were selected to present their solutions at the World Economic Forum Annual Meeting 2023 in Davos:
- Epic Cleantec, based in the US, is a water technology company leading the water reuse revolution in the urban built environment. Aaron Tartakovsky, CEO of Epic Cleantec, said: “With the combined challenges of ageing infrastructure, growing urban populations and a rapidly changing climate, the conventional approach to how we manage water is no longer sustainable. Epic is on a mission to ensure that our cities are water-secure for generations to come.” Epic aims to use its next-generation technologies to drive circularity in water use and to work with policy-makers to reshape the water infrastructure in cities.
- Kilimo, based in Argentina, uses big data and machine learning to verify, improve, and offset water usage in agriculture. Tatiana Malvasio, Co-Founder and Chief Operating Officer, said: “As founders from Latin America, we have first-hand experience with the tension between agriculture and water stress in our region. In response to this challenge, we set out to create a product that could help farmers reduce their water usage and be more efficient in their irrigation practices.” Kilimo uses artificial intelligence to help farmers optimize irrigation and then be compensated for their participation in water stewardship initiatives.
The other entrepreneurs to be awarded prize money from HCL and support from UpLink are:
- bNovate Technologies (Switzerland) – An automatic, remote biosensor to monitor and detect bacterial concentration in water supplies
- Indra Water (India) – Electrically driven, decentralized wastewater treatment solution with no added chemicals in its primary treatment
- Majik Water Technologies (Kenya) – An atmospheric water generator system that uses proven condensation-based techniques to capture water moisture from the air
- NatureDots Private Limited: AquaNurch (India) – Derisking fisheries and water managers from ecological stressors, enabling remote-control and real-time monitoring of aqua-farms
- Oneka Technologies (Canada) – A wave-powered desalination solution to produce drinking water using renewable energy created through waves
- Openversum (Switzerland) – A locally assembled and managed membrane filter that removes pathogen heavy metals from water
- RainGrid Inc. (Canada) – Building community-scale, property-based, digital networks for net-zero residential property rainfall runoff while generating verifiable ecosystem credits
- Wateroam Pte Ltd (Singapore) – Production of safe, speedy and high-quality drinking water without electricity
“We are delighted to announce the first beneficiaries of the Aquapreneur Innovation Initiative who have been selected after rigorous deliberation among a large panel of experts,” said Roshni Nadar Malhotra, Chairperson, HCLTech. “The availability of fresh water is rapidly changing worldwide, creating a tenuous future requiring attention from policy-makers, the private sector and the public alike. Having witnessed the efforts of aquapreneurs who are finding solutions to challenges around existing freshwater resources, I am positive that we are all moving in the right direction for the future of our planet. Many congratulations to the top 10 awardees.”
“These innovations are crucial to meet the increasing global demand for clean water and support the transition to a greener economy,” said Olivier Schwab, Managing Director, World Economic Forum. “With water scarcity threatening countries all around the world, it’s essential to identify and empower the innovative start-ups that will help secure access to this precious resource, now and for future generations. The Aquapreneur Innovation Initiative, launched by UpLink and HCL, will connect these world-class innovators to the resources, expertise and vital funding they need to scale and drive truly transformational change.”
About UpLink
UpLink is the open innovation platform of the World Economic Forum, designed to unlock an “entrepreneur revolution” for people and planet by supporting start-ups with innovative solutions for the world’s most pressing issues, as outlined by the UN Sustainable Development Goals. Launched at the World Economic Forum Annual Meeting 2020 in Davos in partnership with Deloitte and Salesforce, UpLink builds bridges between entrepreneurs and the investors, experts and partners who can help scale their ventures.
UpLink sources innovations through a competition framework known as innovation challenges. UpLink has run more than 43 challenges and identified over 350 entrepreneurs with innovative solutions across critical SDG areas including health, food, freshwater, ocean, plastics, education, climate and more.
For more information, visit https://uplink.weforum.org
About HCL Group
Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the eight-bit microprocessor-based computer in 1978. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies – HCLTech, HCL Infosystems and HCL Healthcare. The group generates annual revenues of over $12.3 billion with more than 222,000 employees operating across 60 countries.
HCLTech, a group company, is among the leading global technology companies. It is delivering cutting-edge capabilities centred around digital, engineering and cloud, powered by a broad portfolio of technology services and products across industry segments. HCLTech is a strategic partner of the World Economic Forum.
For further information, visit www.hcl.com
Notes to editors
About the World Economic Forum Annual Meeting 2023
The World Economic Forum Annual Meeting 2023 will convene the world’s foremost leaders under the theme, Cooperation in a Fragmented World.
Find out more about the Annual Meeting 2023 here
Read the Forum Agenda also in French | Spanish | Mandarin | Japanese
Learn about the Forum’s impact
Check out the Forum’s Strategic Intelligence Platform and Transformation Maps
Follow the Forum on Twitter via @wef@davos | Instagram | LinkedIn | TikTok | Weibo | Podcasts
Become a fan of the Forum on Facebook
Watch Forum videos
Subscribe to Forum news releases and podcasts
The World Economic Forum, committed to improving the state of the world, is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business and other leaders of society to shape global, regional and industry agendas. (www.weforum.org).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005448/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
